The safety and efficacy of hydroxyethyl starch (HES) for fluid resuscitation have not been fully evaluated, and adverse effects of HES on survival and renal function have been reported.
The Hemobag® technology allows the open-heart team to safely concentrate the residual CPB circuit contents and quickly return a high volume of clotting factors and blood cells back to the patient.
